Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs
- PMID: 38580157
- DOI: 10.1016/j.tvjl.2024.106104
Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs
Abstract
We are writing to express our interest in the article entitled "Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs", published in the October, 2021 issue of The Veterinary Journal, Volume 276, 105733, by Krautmann and others.
Keywords: Bedinvetmab; Librela; RPOA; Rapidly progressive osteoarthritis.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Comment in
-
Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.Vet J. 2024 Aug;306:106175. doi: 10.1016/j.tvjl.2024.106175. Epub 2024 Jun 15. Vet J. 2024. PMID: 38885831
Comment on
-
Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.Vet J. 2021 Oct;276:105733. doi: 10.1016/j.tvjl.2021.105733. Epub 2021 Aug 12. Vet J. 2021. PMID: 34391918
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources